Crizotinib (PF-2341066, abbreviated ‘PF' in the text) is a dual kinase inhibitor for ALK and c-MET that is highly cytotoxic for ALK-positive ALCL cells in vitro and in vivo.18 To determine whether crizotinib (PF) and P36 could synergize in ALK-positive tumor cells, we examined the effect of single drug and combination treatments on the viability of Cost ALCL and SH-SY5Y neuroblastoma cells after 48 h exposure. The gene discussed is MET; the disease is anaplastic large cell lymphoma.